Top

Published in:

01-07-2009 | Original Paper

Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case–control study

Authors: Maria Dalamaga, Ilias Migdalis, Jessica L. Fargnoli, Evangelia Papadavid, Erica Bloom, Nicholas Mitsiades, Konstantinos Karmaniolas, Nicolaos Pelecanos, Sofia Tseleni-Balafouta, Amalia Dionyssiou-Asteriou, Christos S. Mantzoros

Published in: Cancer Causes & Control | Issue 5/2009

Abstract

Obesity and insulin resistance have been implicated in the etiology of pancreatic cancer (PC). Whether adiponectin and/or leptin, two adipocyte-secreted hormones important in metabolic regulation, are associated with PC pathogenesis and whether adiponectin receptors are expressed in PC remains unknown. In a hospital-based case–control study, we studied 81 cases with incident, histologically confirmed PC and 81 controls matched on gender and age between 2000 and 2007 to investigate the role of adiponectin and leptin adjusting for risk factors linked to PC. In a separate study, we also studied for the first time whether adiponectin receptors 1 and 2 are expressed in PC by studying 16 PC tumor tissue samples which were analyzed using immunohistochemistry. When subjects were divided into control-defined quartiles of adiponectin and leptin, lower leptin but higher adiponectin levels were associated with PC (p = 0.001 and p = 0.05 respectively) before and after controlling for age, gender, BMI, smoking status, alcohol consumption, history of diabetes, and family history of pancreatic cancer. Of the PC tumor tissue samples analyzed, 87.5% had positive or strong positive expression of AdipoR1 and 93.7% had positive or strong positive expression of AdipoR2. Further prospective studies are needed to determine whether the elevated adiponectin and low leptin levels reported in this study reflect compensatory changes during PC progression and thus can be used as markers for PC or whether they are causally implicated in PC.

Jemal A, Tiwari RC, Murray T et al (2004) Cancer statistics, 2004. CA Cancer J Clin 54:8–29PubMedCrossRef

Warshaw AL, Fernandez-del CC (1992) Pancreatic carcinoma. N Engl J Med 326:455–465PubMed

Schima W, Ba-Ssalamah A, Kolblinger C, Kulinna-Cosentini C, Puespoek A, Gotzinger P (2007) Pancreatic adenocarcinoma. Eur Radiol 17:638–649. doi:10.1007/s00330-006-0435-7 PubMedCrossRef

Freelove R, Walling AD (2006) Pancreatic cancer: diagnosis and management. Am Fam Physician 73:485–492PubMed

Fuchs CS, Colditz GA, Stampfer MJ et al (1996) A prospective study of cigarette smoking and the risk of pancreatic cancer. Arch Intern Med 156:2255–2260. doi:10.1001/archinte.156.19.2255 PubMedCrossRef

Kalapothaki V, Tzonou A, Hsieh CC, Toupadaki N, Karakatsani A, Trichopoulos D (1993) Tobacco, ethanol, coffee, pancreatitis, diabetes mellitus, and cholelithiasis as risk factors for pancreatic carcinoma. Cancer Causes Control 4:375–382. doi:10.1007/BF00051341 PubMedCrossRef

Everhart J, Wright D (1995) Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 273:1605–1609. doi:10.1001/jama.273.20.1605 PubMedCrossRef

Berrington de Gonzalez A, Sweetland S, Spencer E (2003) A meta-analysis of obesity and the risk of pancreatic cancer. Br J Cancer 89:519–523. doi:10.1038/sj.bjc.6601140 PubMedCrossRef

Larsson SC, Orsini N, Wolk A (2007) Body mass index and pancreatic cancer risk: a meta-analysis of prospective studies. Int J Cancer 120:1993–1998. doi:10.1002/ijc.22535 PubMedCrossRef

10.

Hanley AJ, Johnson KC, Villeneuve PJ, Mao Y (2001) Physical activity, anthropometric factors and risk of pancreatic cancer: results from the Canadian enhanced cancer surveillance system. Int J Cancer 94:140–147. doi:10.1002/ijc.1446 PubMedCrossRef

11.

Stolzenberg-Solomon RZ, Graubard BI et al (2005) Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 294:2872–2878. doi:10.1001/jama.294.22.2872 PubMedCrossRef

12.

Tersmette AC, Petersen GM, Offerhaus GJ et al (2001) Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 7:738–744PubMed

13.

Lowenfels AB, Maisonneuve P, DiMagno EP et al (1997) Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 89:442–446. doi:10.1093/jnci/89.6.442 PubMedCrossRef

14.

Matarese G, Mantzoros C, La Cava A (2007) Leptin and adipocytokines: bridging the gap between immunity and atherosclerosis. Curr Pharm Des 13:3676–3680. doi:10.2174/138161207783018635 PubMedCrossRef

15.

Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89:2548–2556. doi:10.1210/jc.2004-0395 PubMedCrossRef

16.

Brennan AM, Mantzoros CS (2006) Drug Insight: the role of leptin in human physiology and pathophysiology–emerging clinical applications. Nat Clin Pract Endocrinol Metab 2:318–327. doi:10.1038/ncpendmet0196 PubMedCrossRef

17.

Barb D, Williams CJ, Neuwirth AK, Mantzoros CS (2007) Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr 86:s858–s866PubMed

18.

Mantzoros C, Petridou E, Dessypris N et al (2004) Adiponectin and breast cancer risk. J Clin Endocrinol Metab 89:1102–1107. doi:10.1210/jc.2003-031804 PubMedCrossRef

19.

Dal Maso L, Augustin LS, Karalis A et al (2004) Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 89:1160–1163. doi:10.1210/jc.2003-031716 PubMedCrossRef

20.

Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, Bedir S (2005) Prostate cancer and adiponectin. Urology 65:1168–1172. doi:10.1016/j.urology.2004.12.053 PubMedCrossRef

21.

Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K, Nagawa H (2005) Plasma adiponectin and gastric cancer. Clin Cancer Res 11:466–472. doi:10.1158/1078-0432.CCR-04-1453 PubMedCrossRef

22.

Spyridopoulos TN, Petridou ET, Skalkidou A, Dessypris N, Chrousos GP, Mantzoros CS (2007) Low adiponectin levels are associated with renal cell carcinoma: a case-control study. Int J Cancer 120:1573–1578. doi:10.1002/ijc.22526 PubMedCrossRef

23.

Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS (2005) Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 97:1688–1694PubMedCrossRef

24.

Mantzoros CS, Trakatelli M, Gogas H et al (2007) Circulating adiponectin levels in relation to melanoma: a case-control study. Eur J Cancer 43:1430–1436. doi:10.1016/j.ejca.2007.03.026 PubMedCrossRef

25.

Petridou E, Mantzoros CS, Dessypris N, Dikalioti SK, Trichopoulos D (2006) Adiponectin in relation to childhood myeloblastic leukaemia. Br J Cancer 94:156–160. doi:10.1038/sj.bjc.6602896 PubMedCrossRef

26.

Dalamaga M, Nikolaidou A, Karmaniolas K et al (2007) Circulating adiponectin and leptin in relation to myelodysplastic syndrome: a case-control study. Oncology 73(1–2):26–32. doi:10.1159/000120995 PubMedCrossRef

27.

Chang MC, Chang YT, Su TC et al (2007) Adiponectin as a potential differential marker to distinguish pancreatic cancer and chronic pancreatitis. Pancreas 35:16–21. doi:10.1097/MPA.0b013e3180547709 PubMedCrossRef

28.

Greene FL, American Joint Committee on Cancer ACS (2002) AJCC cancer staging manual, 6th edn. Springer, New York, pp 157–165

29.

Stolzenberg-Solomon RZ, Weinstein S, Pollak M et al (2008) Prediagnostic adiponectin concentrations and pancreatic cancer risk in male smokers. Am J Epidemiol (in press)

30.

Stolzenberg-Solomon RZ, Pietinen P, Taylor PR, Virtamo J, Albanes D (2002) A prospective study of medical conditions, anthropometry, physical activity, and pancreatic cancer in male smokers (Finland). Cancer Causes Control 13:417–426. doi:10.1023/A:1015729615148 PubMedCrossRef

31.

Costacou T, Zgibor JC, Evans RW et al (2005) The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh epidemiology of diabetes complications study. Diabetologia 48:41–48. doi:10.1007/s00125-004-1597-y PubMedCrossRef

32.

Fryzek JP, Schenk M, Kinnard M, Greenson JK, Garabrant DH (2005) The association of body mass index and pancreatic cancer in residents of southeastern Michigan, 1996–1999. Am J Epidemiol 162:222–228. doi:10.1093/aje/kwi183 PubMedCrossRef

33.

Michaud DS, Wolpin B, Giovannucci E et al (2007) Prediagnostic plasma C-peptide and pancreatic cancer risk in men and women. Cancer Epidemiol Biomarkers Prev 16:2101–2109. doi:10.1158/1055-9965.EPI-07-0182 PubMedCrossRef

34.

Lin Y, Tamakoshi A, Kikuchi S et al (2004) Serum insulin-like growth factor-I, insulin-like growth factor binding protein-3, and the risk of pancreatic cancer death. Int J Cancer 110:584–588. doi:10.1002/ijc.20147 PubMedCrossRef

35.

Pilz S, Mangge H, Wellnitz B et al (2006) Adiponectin and mortality in patients undergoing coronary angiography. J Clin Endocrinol Metab 91:4277–4286. doi:10.1210/jc.2006-0836 PubMedCrossRef

36.

Kistorp C, Faber J, Galatius S et al (2005) Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 112:1756–1762. doi:10.1161/CIRCULATIONAHA.104.530972 PubMedCrossRef

37.

Menon V, Li L, Wang X et al (2006) Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 17:2599–2606. doi:10.1681/ASN.2006040331 PubMedCrossRef

38.

Wolf I, Sadetzki S, Kanety H et al (2006) Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer 106:966–973. doi:10.1002/cncr.21690 PubMedCrossRef

39.

Brichard SM, Delporte ML, Lambert M (2003) Adipocytokines in anorexia nervosa: a review focusing on leptin and adiponectin. Horm Metab Res 35:337–342. doi:10.1055/s-2003-41353 PubMedCrossRef

40.

Barber MD, McMillan DC, Wallace AM, Ross JA, Preston T, Fearon KC (2004) The response of leptin, interleukin-6 and fat oxidation to feeding in weight-losing patients with pancreatic cancer. Br J Cancer 90:1129–1132. doi:10.1038/sj.bjc.6601712 PubMedCrossRef

41.

Brown DR, Berkowitz DE, Breslow MJ (2001) Weight loss is not associated with hyperleptinemia in humans with pancreatic cancer. J Clin Endocrinol Metab 86:162–166. doi:10.1210/jc.86.1.162 PubMedCrossRef

Title: Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case–control study
Authors: Maria Dalamaga
Ilias Migdalis
Jessica L. Fargnoli
Evangelia Papadavid
Erica Bloom
Nicholas Mitsiades
Konstantinos Karmaniolas
Nicolaos Pelecanos
Sofia Tseleni-Balafouta
Amalia Dionyssiou-Asteriou
Christos S. Mantzoros
Publication date: 01-07-2009
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 5/2009
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-008-9273-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2009

Cancer registration data and quality indicators in low and middle income countries: their interpretation and potential use for the improvement of cancer care

Metabolic factors and subsequent risk of hepatocellular carcinoma by hepatitis virus infection status: a large-scale population-based cohort study of Japanese men and women (JPHC Study Cohort II)

Use of blood-pressure-lowering medication and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort

Season of diagnosis and prognosis in breast and prostate cancer

Predicting lung cancer death in Africa and Asia: differences with WHO estimates

Diet and expression of estrogen alpha and progesterone receptors in the normal mammary gland

Keynote webinar | Spotlight on antibody–drug conjugates in cancer